person · Reporting owner
Katz Michael David M.D.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Hanover Bancorp, Inc. /MDHNVR · Entity 1705 | Director | February 05, 2026 | February 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Hanover Bancorp, Inc. /MD
Report date February 05, 2026 · Filed February 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 152,202 |
Reported balance
After 2026-02-05 transaction · row 1
1 source rowRow 1 · 2026-02-05 · Grant · Acquired 1,592 · Balance 152,202 F1: Represents a grant of restricted stock subject to forfeiture, vesting over a three year period, with 1/3 vesting on each of March 1, 2027, March 1, 2028, and March 1, 2029. |
| Common StockSEC Table I · non-derivative | IndirectBy Custodian for Grandchild #1 | 25 |
Reported balance
Holding disclosure · report date 2026-02-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 25 |
| Common StockSEC Table I · non-derivative | IndirectBy Custodian for Grandchild #2 | 40 |
Reported balance
Holding disclosure · report date 2026-02-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 40 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust - Beneficiary | 96,760 |
Reported balance
Holding disclosure · report date 2026-02-05 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 96,760 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock subject to forfeiture, vesting over a three year period, with 1/3 vesting on each of March 1, 2027, March 1, 2028, and March 1, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2026 Filed Feb 9, 2026 19:48 UTC | Hanover Bancorp, Inc. /MD HNVR · Entity 1705 | GrantCommon Stock | 1,592 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-001514 · doc4.xml · nonDerivative · entry 1 Katz Michael David M.D. · CIK 0001919798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,202 F1 · shares: Represents a grant of restricted stock subject to forfeiture, vesting over a three year period, with 1/3 vesting on each of March 1, 2027, March 1, 2028, and March 1, 2029. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 20:51 UTC | Hanover Bancorp, Inc. /MD HNVR · Entity 1705 | GrantCommon Stock | 1,331 | $0.00 | $0.00 |
DisclosureSEC source: 0001619964-25-000015 · primary_doc.xml · nonDerivative · entry 1 Katz Michael David M.D. · CIK 0001919798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,610 F1 · shares: Represents a grant of restricted stock subject to forfeiture, vesting over a five year period, with 1/5 vesting on each of February 20, 2026, February 20, 2027, February 20, 2028, February 20, 2029, and February 20, 2030. Read SEC document |
| December 10, 2024 Filed Dec 11, 2024 18:13 UTC | Hanover Bancorp, Inc. /MD HNVR · Entity 1705 | SaleCommon Stock | 5,000 | $25.53 | $127,650.00 |
DisclosureSEC source: 0001619964-24-000044 · primary_doc.xml · nonDerivative · entry 1 Katz Michael David M.D. · CIK 0001919798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,279 Read SEC document |
| April 09, 2024 Filed Apr 9, 2024 17:55 UTC | Hanover Bancorp, Inc. /MD HNVR · Entity 1705 | Exercise / conversionNon-Qualified Stock Option · Derivative | 7,057 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001619964-24-000020 · primary_doc.xml · derivative · entry 5 Katz Michael David M.D. · CIK 0001919798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,057 shares Expires 2024-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2024 Filed Apr 9, 2024 17:55 UTC | Hanover Bancorp, Inc. /MD HNVR · Entity 1705 | Exercise / conversionCommon Stock | 7,057 | $10.00 | $70,570.00 |
DisclosureSEC source: 0001619964-24-000020 · primary_doc.xml · nonDerivative · entry 1 Katz Michael David M.D. · CIK 0001919798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 16:14 UTC | Hanover Bancorp, Inc. /MD HNVR · Entity 1705 | GrantCommon Stock | 2,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001619964-24-000014 · primary_doc.xml · nonDerivative · entry 1 Katz Michael David M.D. · CIK 0001919798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,222 F1 · shares: Represents a grant of restricted stock subject to forfeiture, vesting over a five year period, with 1/5 vesting on each of March 1, 2025, March 1, 2026, March 1, 2027, March 1, 2028, and March 1, 2029 Read SEC document |
| January 29, 2024 Filed Jan 30, 2024 21:08 UTC | Hanover Bancorp, Inc. /MD HNVR · Entity 1705 | PurchaseCommon Stock | 700 | $18.02 | $12,614.00 |
DisclosureSEC source: 0001619964-24-000006 · primary_doc.xml · nonDerivative · entry 1 Katz Michael David M.D. · CIK 0001919798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,105 Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 20:59 UTC | Hanover Bancorp, Inc. /MD HNVR · Entity 1705 | GrantCommon Stock | 1,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001619964-23-000011 · primary_doc.xml · nonDerivative · entry 1 Katz Michael David M.D. · CIK 0001919798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,405 F1 · shares: Represents a grant of restricted stock subject to forfeiture, vesting over a five year period, with 1/5 vesting on each of February 20, 2024, February 20, 2025, February 20, 2026, February 20, 2027, and February 20, 2028. Read SEC document |
| August 12, 2022 Filed Aug 15, 2022 19:48 UTC | Hanover Bancorp, Inc. /MD HNVR · Entity 1705 | PurchaseCommon Stock | 40 | $20.11 | $804.40 |
DisclosureSEC source: 0001619964-22-000033 · primary_doc.xml · nonDerivative · entry 2 Katz Michael David M.D. · CIK 0001919798 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote 1 Disclosed balance after: 65 F1 · ownership.nature: Held as custodian for Dr. Katz's grandchild Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 19:48 UTC | Hanover Bancorp, Inc. /MD HNVR · Entity 1705 | PurchaseCommon Stock | 25 | $19.99 | $499.73 |
DisclosureSEC source: 0001619964-22-000033 · primary_doc.xml · nonDerivative · entry 1 Katz Michael David M.D. · CIK 0001919798 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote 1 Disclosed balance after: 25 F1 · ownership.nature: Held as custodian for Dr. Katz's grandchild Read SEC document |
| May 11, 2022 Filed May 11, 2022 15:40 UTC | Hanover Bancorp, Inc. /MD HNVR · Entity 1705 | PurchaseCommon Stock | 5,000 | $21.00 | $105,000.00 |
DisclosureSEC source: 0001619964-22-000021 · primary_doc.xml · nonDerivative · entry 1 Katz Michael David M.D. · CIK 0001919798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,793 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.